Luminoah and Rivanna emerge from a field of 1,400 global applicants, as two of the five MedTech Innovator competition finalists, putting Charlottesville’s medtech hub on the global stage.
In a striking affirmation of its growing biotech stature, Charlottesville is home to two of the five companies selected as finalists in the 2025 MedTech Innovator (MTI) Grand Prize competition: Luminoah and Rivanna. The distinction signals not only a win for those companies but also a boost to the region’s ecosystem presence as a leading medtech hub.
Of more than 1,400 applicants, only 64 companies were accepted into MTI’s 2025 accelerator cohort—just 4% of the pool—and from that group, five advanced to the Grand Prize stage. Each finalist receives a $25,000 award and competes on the main stage at The MedTech Conference, where a live audience of industry leaders determines the $350,000 non-dilutive Grand Prize winner.
Luminoah has drawn particular attention in the Charlottesville community. Its CEO, Neal Piper, described the milestone as “standing before more than 1,000 healthcare leaders… elevating the voices of millions who rely on enteral nutrition every day and sharing Luminoah’s vision to transform nutrition delivery.” In his LinkedIn post, Piper noted that Luminoah also won MTI’s Best Video Award, an additional recognition among an impressive peer cohort.
Rivanna’s CEO, Will Mauldin, similarly reflected on the moment: “It was an honor to represent RIVANNA as one of five finalists … alongside an exceptional group of innovators.” Rivanna’s inclusion underscores the technical promise of its imaging-based solutions and the depth of medtech innovation emerging from Charlottesville.
Emerging Technologies, Deep Impact
Luminoah is developing the Luminoah Flow, a compact, smart enteral nutrition delivery system that aims to untether patients from traditional bulky feeding pumps. The device pairs with a mobile app for real-time monitoring and insight, offering “the world’s smallest, smartest enteral nutrition delivery system” designed for discreet, everyday use. The company raised a $6 million Series A round in 2023, led by Fry’s Path Capital and supported by Sands Capital, CAV Angels, Virginia Venture Partners, and 757 Angels. Piper has often cited the personal inspiration behind the vision—his son Noah’s history with enteral feeding—as foundational to Luminoah’s mission.
Rivanna, founded by University of Virginia alumni, has built the Accuro platform: a handheld ultrasound device with AI-enabled guidance for neuraxial procedures, such as epidurals, and other imaging applications. The technology enhances bone-to-tissue contrast and automates landmark identification, reportedly increasing first-attempt success rates and reducing needle redirections. In 2024, Rivanna initiated a multi-site first-in-human study of its Accuro XV device, targeting bedside fracture imaging without radiation. The platform is backed by a $30.5 million funding option from the Biomedical Advanced Research and Development Authority (BARDA) and is FDA-cleared for spinal anesthesia and additional anatomies.
Why Finalist Status Matters
Even before the Grand Prize is awarded, being named a finalist confers distinct advantages. MTI describes its accelerator as a platform for “risk mitigation and value creation,” offering startups exposure to mentors, corporates, payers, and providers—while bolstering their credibility with investors. Alumni from past cohorts have launched more than 400 products and raised over $10 billion in follow-on funding.
As Piper noted, it took more than just entry into the program: “It was the closest vote in MTI history—congratulations to Kelsey Mayo from Armor Medical on a well-earned win.” He also thanked MTI’s leadership and mentors, including teams from Dexcom, PRIA Healthcare, Cannon Quality Group, and others, for their role in shaping the cohort.
What This Means for Charlottesville’s Biotech Ecosystem
Traditionally, biotech magnet regions—Boston, San Francisco, and San Diego—dominate medtech headlines. But for Charlottesville to house two of five MTI finalists suggests momentum at a regional level. It validates local infrastructure: capital, universities, talent, and an innovation culture that supports commercialization.
To translate this success into sustained growth, the ecosystem will need to double down on supporting clinical validation, regulatory navigation, reimbursement strategy, and commercialization partnerships. The visibility from MTI may help draw more entrepreneurial talent, investors, and industry collaborators to Central Virginia.
Beyond the immediate spotlight, Luminoah and Rivanna may serve as anchor success stories—proof that breakthrough medtech innovation can emerge from Virginia. Their trajectories in the next year, from clinical trials to regulatory milestones and partnerships, will serve as a barometer not just for their companies but for the region’s long-term biotech ambitions.
